BRUCE C. COZADD - 03 Oct 2022 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role: Chairman & CEO, Director
Signature: By: /s/Paz Dizon, as attorney in fact For: Bruce C Cozadd
Issuer symbol: JAZZ
Transactions as of: 03 Oct 2022
Net transactions value: -$2,377,334
Form type: 4
Filing time: 05 Oct 2022, 18:43:30 UTC
Previous filing: 08 Sep 2022
Next filing: 14 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	JAZZ	Ordinary Shares	Options Exercise	$3,719,573	+62,905	+18%	$59.13	419,213	03 Oct 2022	Direct
transaction	JAZZ	Ordinary Shares	Sale	$1,848,307	-13,791	-3.3%	$134.02	405,422	03 Oct 2022	Direct	F1, F2
transaction	JAZZ	Ordinary Shares	Sale	$3,196,386	-23,646	-5.8%	$135.18	381,776	03 Oct 2022	Direct	F1, F3
transaction	JAZZ	Ordinary Shares	Sale	$1,052,213	-7,748	-2%	$135.80	374,028	03 Oct 2022	Direct	F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JAZZ	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-62,905	-100%	$0.000000^*	0	03 Oct 2022	Ordinary Shares	62,905	$59.13	Direct	F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options.
F2	Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $133.56 to $134.54. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3	Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $134.57 to $135.56. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4	Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $135.57 to $136.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5	This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F6	This non-qualified stock option is part of an option granted on March 5, 2013. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of March 5, 2017.